Search

Search Constraints

You searched for: Author/Creator Reder, Anthony

Search Results

2. NCMP-08. CLINICAL FEATURES OF CAR T-CELL THERAPY NEUROTOXICITY AS POTENTIAL SURROGATE MARKERS FOR PROGRESSION AND OUTCOME. (11th November 2019)

3. NCMP-18. NEUROTOXICITY AS A POTENTIAL SURROGATE MARKER FOR THERAPEUTIC RESPONSE WITH COMMERCIAL ANTI-CD19 CAR T-CELL THERAPY. (9th November 2020)

4. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2020)